

LINDA LINGLE
GOVERNOR



LILLIAN B. KOLLER, ESQ.
DIRECTOR

HENRY OLIVA
DEPUTY DIRECTOR


STATE OF HAWAII
DEPARTMENT OF HUMAN SERVICES
Med-QUEST Division
Clinical Standards Office
P. O. Box 700190
Kapolei, Hawaii 96709-0190

August 28, 2008

MEMORANDUM

ACS M08-11

TO: Medicaid Fee-For-Service (FFS) and QUEST Physicians and Pharmacies

FROM: Kenneth S. Fink, MD, MGA, MPH 
Med-QUEST Division Administrator

Anthea Wang, MD, MPH
Med-QUEST Division Medical Director

SUBJECT: Fee-For-Service and QUEST Programs

**PREVENTION OF SERIOUS LOWER RESPIRATORY TRACT
INFECTIONS CAUSED BY RESPIRATORY SYNCYTIAL VIRUS
(RSV)**

This memorandum updates and supercedes previous guidelines for the coverage of RSV prophylaxis.

Synagis® (Palvizumab) administered intramuscularly, is approved by the Federal Drug Administration (FDA) for the prevention of serious lower respiratory tract infections in infants. The guidelines that follow were developed based on Hawaii's experience with Synagis®.

The following guidelines for the prevention of RSV and coverage of Synagis® by the Hawaii QUEST medical plans and the Fee-For-Service (FFS) Medicaid program have been developed by the medical directors of the QUEST medical plans and the Med-QUEST Division (MQD). They are based on the guidelines for prophylaxis of RSV infections in high risk infants in Hawaii developed by the Consensus Committee during its meeting on July 15, 2008. The Consensus Committee is comprised of physicians associated with the Department of Pediatrics of the University of Hawaii, School of Medicine with expertise in RSV infections in Hawaii.

General Prevention

Parents and caregivers of former premature infants, infants with bronchopulmonary dysplasia, and infants with congenital heart disease should receive education in the following:

- Strict hand washing techniques;
- Avoidance of unnecessary exposure of their infants to crowds;
- Avoidance of exposure to their infants to smoke and dust, especially passive smoke exposure in presence of smokers in the family; and
- Avoidance of exposure of their infants to all sick persons, especially those with respiratory symptoms.

Patient Population

Patients who should be considered for RSV prophylaxis should be in one or more of the following groups:

- Infants and children younger than two (2) years of age at the start of the RSV season with Chronic Lung Disease (CLD) requiring significant medical therapy, such as oxygen for treatment of their CLD, within six (6) months before the anticipated RSV season (born on or after September 15, 2006; continuing medical treatment after March 15, 2008).
- Infants and children younger than two (2) years of age at the start of the RSV season with hemodynamically significant Congenital Heart Disease (CHD) requiring medical management within six (6) months before the anticipated RSV season (born on or after September 15, 2006; continuing medical treatment after March 15, 2008). Infants younger than 12 months with CHD who are most likely to benefit from immunoprophylaxis include:
 - Infants who are receiving medication to control congestive heart failure;
 - Infants with moderate to severe pulmonary hypertension; and
 - Infants with cyanotic heart disease.
- Infants born prematurely at 28 weeks gestation or earlier and who are less than 12 months chronological age at the start of the RSV season (born on or after September 15, 2007).
- Infants born prematurely between 29 and 32 weeks gestation and who are less than six (6) months chronological age at the start of the RSV season (born on or after March 15, 2008). The definition of 32 weeks is an infant born on or before the 32nd week of gestation (i.e., 32 + 0 weeks).
- Infants born prematurely between 33 and 35 weeks gestation requiring significant respiratory support in the neonatal period (positive pressure support) and having at least one (1) of the following additional risk factors – day care attendance, school-aged siblings, congenital abnormalities of the airways, or severe neuromuscular disease – and who are less than six (6) months chronological age at the start of the RSV season (born on or after March 15, 2008).

- There are several children with other illnesses in the Pediatric age group who may be considered for prophylaxis. Pediatricians should evaluate these children on a case-by-case basis and, if necessary, in consultation with an appropriate sub-specialist.
- All children after cardiopulmonary bypass and with indication for use of Synagis® should be considered for additional prophylaxis after discharge. Children with cardiac disease undergoing cardiopulmonary bypass during the season and currently receiving prophylaxis should receive an additional dose of prophylaxis within a few days after bypass and should continue to receive subsequent prophylaxis until the end of the season.

RSV Season

RSV infections occur in the community all year round. Based on available epidemiological data, the incidence is significantly higher from September to February. Therefore, the season for late 2008 to early 2009 this year for Hawaii will be from **September 15, 2008 to February 28, 2009**. The Consensus Committee will meet again in late January 2009 to evaluate, utilizing available data, whether or not the RSV season needs to be extended.

Recommended Prophylaxis

- Prophylaxis should start no earlier than September 15, 2008 and end no later than February 28, 2009. A maximum number of five (5) doses will be covered for the identified regular season. Coverage for Synagis® for an additional dose per month will be allowed after February 28, 2009 only if the RSV season is extended by the Consensus Committee.
- The interval between the first and second dose should be no less than and as close as possible to 28 days. All subsequent dose intervals should be as close as possible to 30 days with the range being 28-35 days.
- When children meet criteria for prophylaxis based on their age, prophylaxis should be continued for the duration of the RSV season.
- Should a child develop RSV during the course of the season, prophylaxis should resume after recovery until the end of the season.

Additional Considerations

- The MQD requires authorization for Synagis®. For FFS providers, authorization must be obtained from Affiliated Computer Services (ACS), the MQD's pharmacy fiscal agent. Requests for prior authorization should be faxed on the 1144B (Attachment 1) to 1-888-335-8474. For QUEST providers, authorizations for Synagis® must be obtained from the child's QUEST medical plan.

- Prior authorization will cover Synagis[®] doses in intervals of 28-35 days during the RSV season from September 15, 2008 to February 28, 2009. If the season is extended by the Consensus Committee, the end date on the prior authorization will be changed to reflect the end date specified by the committee, and additional doses will then be covered up to the revised end date. A second prior authorization will *not* be required.
- Families should be educated that although prophylaxis is not 100% effective, it may lead to a decrease in severity of subsequent illness. Consideration should be given to obtaining an informed consent prior to drug administration.
- Vulnerable children meeting criteria for RSV prophylaxis should also be considered for influenza vaccine in addition to RSV prophylaxis if they are over the age of six (6) months.
- As Synagis[®] is given intramuscularly, it must be used with caution in patients with thrombocytopenia and coagulation disorders.

Attachment

REQUEST FOR MEDICAL AUTHORIZATION

Check only One - Different Types of Services Must Be Requested on Separate 1144B Forms. Home Infusion PA Non-home infusion (Medication only) PA

NOTE: INCOMPLETE FORM WILL DELAY THE AUTHORIZATION PROCESS. Approval of this request is not an authorization for payment or an approval of charges. Payment by the Medicaid Program is contingent on the patient being eligible and the provider of service being certified by Medicaid. The provider of service must verify patient eligibility at the time the service is rendered. Authorization expires 60 days from date of approval unless otherwise noted by the consultant.

1 Medicaid ID Number		2 Recipient's Name (Last, First, M.I.)		3 Gender <input type="checkbox"/> M <input type="checkbox"/> F		4 Date of Birth / /	
5 Medicare Coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No Is Patient receiving Medicare Home Health Benefits? <input type="checkbox"/> Yes <input type="checkbox"/> No		6 Currently at: <input type="checkbox"/> Home <input type="checkbox"/> Hospital <input type="checkbox"/> SNF/ICF/CF-MR Facility Recipient's Mailing Address (St., City, Zip Code)		7 Expanded Early & Periodic Screening Diagnosis & Treatment (EPSDT): <input type="checkbox"/> Yes <input type="checkbox"/> No			
8 NDC Number or Drug Name, Strength, Units, Global Code, or HCPCS code		9 QTY		10 Purchase Price		11 Supplier Section (Circle Rent/Repair) 11 Rent/Repair	
12		13		14		15	
16		17		18		19	
20		21		22		23	
24		25		26		27	
28		29		30		31	
32		33		34		35	
36		37		38		39	
40		41		42		43	
44		45		46		47	
48		49		50		51	
52		53		54		55	
56		57		58		59	
60		61		62		63	
64		65		66		67	
68		69		70		71	
72		73		74		75	
76		77		78		79	
80		81		82		83	
84		85		86		87	
88		89		90		91	
92		93		94		95	
96		97		98		99	
100		101		102		103	
104		105		106		107	
108		109		110		111	
112		113		114		115	
116		117		118		119	
120		121		122		123	
124		125		126		127	
128		129		130		131	
132		133		134		135	
136		137		138		139	
140		141		142		143	
144		145		146		147	
148		149		150		151	
152		153		154		155	
156		157		158		159	
160		161		162		163	
164		165		166		167	
168		169		170		171	
172		173		174		175	
176		177		178		179	
180		181		182		183	
184		185		186		187	
188		189		190		191	
192		193		194		195	
196		197		198		199	
200		201		202		203	
204		205		206		207	
208		209		210		211	
212		213		214		215	
216		217		218		219	
220		221		222		223	
224		225		226		227	
228		229		230		231	
232		233		234		235	
236		237		238		239	
240		241		242		243	
244		245		246		247	
248		249		250		251	
252		253		254		255	
256		257		258		259	
260		261		262		263	
264		265		266		267	
268		269		270		271	
272		273		274		275	
276		277		278		279	
280		281		282		283	
284		285		286		287	
288		289		290		291	
292		293		294		295	
296		297		298		299	
300		301		302		303	
304		305		306		307	
308		309		310		311	
312		313		314		315	
316		317		318		319	
320		321		322		323	
324		325		326		327	
328		329		330		331	
332		333		334		335	
336		337		338		339	
340		341		342		343	
344		345		346		347	
348		349		350		351	
352		353		354		355	
356		357		358		359	
360		361		362		363	
364		365		366		367	
368		369		370		371	
372		373		374		375	
376		377		378		379	
380		381		382		383	
384		385		386		387	
388		389		390		391	
392		393		394		395	
396		397		398		399	
400		401		402		403	
404		405		406		407	
408		409		410		411	
412		413		414		415	
416		417		418		419	
420		421		422		423	
424		425		426		427	
428		429		430		431	
432		433		434		435	
436		437		438		439	
440		441		442		443	
444		445		446		447	
448		449		450		451	
452		453		454		455	
456		457		458		459	
460		461		462		463	
464		465		466		467	
468		469		470		471	
472		473		474		475	
476		477		478		479	
480		481		482		483	
484		485		486		487	
488		489		490		491	
492		493		494		495	
496		497		498		499	
500		501		502		503	
504		505		506		507	
508		509		510		511	
512		513		514		515	
516		517		518		519	
520		521		522		523	
524		525		526		527	
528		529		530		531	
532		533		534		535	
536		537		538		539	
540		541		542		543	
544		545		546		547	
548		549		550		551	
552		553		554		555	
556		557		558		559	
560		561		562		563	
564		565		566		567	
568		569		570		571	
572		573		574		575	
576		577		578		579	
580		581		582		583	
584		585		586		587	
588		589		590		591	
592		593		594		595	
596		597		598		599	
600		601		602		603	
604		605		606		607	
608		609		610		611	
612		613		614		615	
616		617		618		619	
620		621		622		623	
624		625		626		627	
628		629		630		631	
632		633		634		635	
636		637		638		639	
640		641		642		643	
644		645		646		647	
648		649		650		651	
652		653		654		655	
656		657		658		659	
660		661		662		663	
664		665		666		667	
668		669		670		671	
672		673		674		675	
676		677		678		679	
680		681		682		683	
684		685		686		687	
688		689		690		691	
692		693		694		695	
696		697		698		699	
700		701		702		703	
704		705		706		707	
708		709		710		711	
712		713		714		715	
716		717		718		719	
720		721		722		723	
724		725		726		727	
728		729		730		731	
732		733		734		735	
736		737		738		739	
740		741		742		743	
744		745		746		747	
748		749		750		751	
752		753		754		755	
756		757		758		759	
760		761		762		763	
764		765		766		767	
768		769		770		771	
772		773		774		775	
776		777		778		779	
780		781		782		783	
784		785		786		787	
788		789		790		791	
792		793		794		795	
796		797		798		799	
800		801		802		803	
804		805		806		807	
808		809		810		811	
812		813		814		815	
816		817		818		819	
820		821		822		823	
824		825		826		827	
828		829		830		831	
832		833		834		835	
836		837		838		839	
840		841		842		843	
844		845		846		847	
848		849		850		851	
852		853		854		855	
856		857		858		859	
860		861		862		863	

FORM INSTRUCTIONS
DHS 1144B (Rev. 03/07)
Request for Medical Authorization of Home Infusion or
Medication Prior Authorization (PA)

PURPOSE:

Fee For Service program request for medical authorization of home infusion or medication PA.

FORM INSTRUCTIONS:

1. **Medicaid ID Number:** Enter the Medicaid I.D.
2. **Recipient's Name:** Enter the recipient's name (Last, First, MI).
3. **Gender:** Check the recipient's gender.
4. **Date of Birth:** Enter the recipient's date of birth: mm/dd/yyyy.
5. **Medicare Coverage:** Check whether the recipient has Medicare coverage and is receiving Medicare Home Health Benefits.
6. **Currently At:** Check where the recipient is currently located and enter the mailing address.
7. **Expanded Early & Periodic Screening Diagnosis & Treatment (EPSDT):** Check whether the recipient has received expanded early and periodic screening diagnosis & treatment.
8. **NDC Number or Drug Name, Strength, Units, or Global Code, or HCPCS:** Enter the NDC Number and units or Drug Name with strength and units, or Global Code and units, or HCPCS Code and units.
9. **QTY:** Enter the quantity.
10. **Purchase Price:** Enter the purchase price.
11. **Rent/Repair:** Circle whether this request is for rent or repair and enter the amount.
12. **Period Requested:** Enter the Period Requested From: and To:.
13. **Diagnosis or ICD-9 code:** Enter the diagnosis code or the ICD-9 code.
14. **BMI (for anorexiant):** Enter the BMI.
15. **Period Requested:** Enter the period requested.
16. **Prognosis:** Enter the prognosis.
17. **Justification:** Enter the justification and include any history of previous treatment. Check if any attachments are included.
18. **Print Prescriber's Name / Mailing Address:** Print the prescriber's name and mailing address.
19. **Prescriber's Signature:** Prescriber's: Sign the form.
20. **Prescriber's NPI:** Enter the prescriber's National Provider Identifier (NPI).
21. **Date:** Enter the date of signature.
22. **Telephone #:** Enter the prescriber's telephone number.
23. **Fax #:** Enter the prescriber's fax number.
24. **Contact Name:** Enter the name of the person to contact.
25. **Print Supplier's Name / Mailing Address:** Print the supplier's name and mailing address.
26. **Comments:** Enter any comments.
27. **Contact Name:** Enter the name of the person to contact at the supplier.
28. **Telephone #:** Enter the supplier's telephone number.
29. **Fax#:** Enter the supplier's fax number.
30. **Supplier's Signature:** Sign the request.
31. **Supplier's NPI:** Enter the supplier's or pharmacy's NPI.
32. **Date:** Enter the date of signature.

FILING INSTRUCTIONS:

1. Retain the original hard copy and submit by fax to ACS at 1(888)335-8474;

OR

2. Retain a copy and submit by mail the original hard copy to:

ACS
Hawaii State Medicaid Fee for Service Program
Attn: DUR
P.O. Box 967
Henderson, NC 27536-0967